

28 November 2013

ASX ANNOUNCEMENT

R&D TAX INCENTIVE

The Board of Actinogen Limited (ASX: ACW) is pleased to advise that the Company has today received an R&D Tax Incentive refund of \$146,954 for the 2012/2013 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 45% of eligible expenditure on research and development.

The proceeds of the incentive refund will be used for the relocation of the laboratory to new facilities, the re-establishment of the scientific research team, headed by the Dr David Keast, a founder of the Actinogen projects, and for general administration and working capital requirements for the continuation of the research and development of the Company's focal projects.

Peter Webse
Company Secretary
Actinogen Limited

About Actinogen Limited Actinogen Limited (ASX: ACW)

Actinogen is dedicated to the discovery and isolation of a group of environmental bacteria known as the Actinomycetes. Actinomycetes have been shown to be able to use a wide range of unusual nutritional resources and often produce bioactive molecules as a by-product that have been proven to be useful to man; including well known commercial examples such as bacterial antibiotics, anti fungal agents, anticancer agents and a variety of other chemicals that are used in the control of physiological and physical processes.

In addition, there are examples of Actinomycetes that can degrade industrial wastes such as oils, tar, domestic and industrial waste, and the rehabilitation of oil spills. Actinogen has proven high-level expertise in the discovery and isolation of Actinomycetes from WA soils and in the detection of bioactive molecules they produce. During 2011, Actinogen began a bio-ethanol research program, which has had very encouraging results and to date is a focal project for the company. The Company's strategy is to collaborate with groups nationally and internationally who are active in the development of technology that is synergistic with or that could utilise the Company's current Actinomycetes research projects and exclusive intellectual property.